AUPH Aurinia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AUPH

Price (delayed)

$11.2

Market cap

$1.59B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.28

Enterprise value

$1.46B

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The ...

Highlights
Aurinia Pharmaceuticals's gross profit has increased by 46% from the previous quarter and by 28% YoY
The revenue has increased by 45% from the previous quarter and by 30% YoY
The net income has decreased by 32% YoY but it has increased by 7% from the previous quarter
Aurinia Pharmaceuticals's EPS has decreased by 24% YoY but it has increased by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.auriniapharma.com
Peers: QURE LXRX

Key stats

What are the main financial stats of AUPH
Market
Shares outstanding
141.74M
Market cap
$1.59B
Enterprise value
$1.46B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.54
Price to sales (P/S)
23.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.07
Earnings
Revenue
$66.32M
EBIT
-$167.46M
EBITDA
-$164.54M
Free cash flow
-$151.3M
Per share
EPS
-$1.28
Free cash flow per share
-$1.07
Book value per share
$3.16
Revenue per share
$0.47
TBVPS
$3.52
Balance sheet
Total assets
$506.9M
Total liabilities
$58.78M
Debt
$8.57M
Equity
$448.12M
Working capital
$443.78M
Liquidity
Debt to equity
0.02
Current ratio
14.11
Quick ratio
12.98
Net debt/EBITDA
0.75
Margins
EBITDA margin
-248.1%
Gross margin
98%
Net margin
-253.7%
Operating margin
-253.4%
Efficiency
Return on assets
-37.5%
Return on equity
-43.2%
Return on invested capital
-60.2%
Return on capital employed
-35.4%
Return on sales
-252.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AUPH stock price

How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
-2.95%
1 week
5.36%
1 month
-0.97%
1 year
-22.44%
YTD
-51.03%
QTD
-9.53%

Financial performance

How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$66.32M
Gross profit
$65.02M
Operating income
-$168.07M
Net income
-$168.22M
Gross margin
98%
Net margin
-253.7%
Aurinia Pharmaceuticals's gross profit has increased by 46% from the previous quarter and by 28% YoY
The revenue has increased by 45% from the previous quarter and by 30% YoY
Aurinia Pharmaceuticals's net margin has increased by 36% QoQ
The operating margin has increased by 36% from the previous quarter

Growth

What is Aurinia Pharmaceuticals's growth rate over time

Valuation

What is Aurinia Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.54
P/S
23.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.07
Aurinia Pharmaceuticals's EPS has decreased by 24% YoY but it has increased by 9% QoQ
The price to book (P/B) is 43% lower than the last 4 quarters average of 6.2 and 25% lower than the 5-year quarterly average of 4.7
AUPH's equity is up by 21% year-on-year but it is down by 6% since the previous quarter
The stock's P/S is 99% less than its 5-year quarterly average of 2366.9 and 40% less than its last 4 quarters average of 39.9
The revenue has increased by 45% from the previous quarter and by 30% YoY

Efficiency

How efficient is Aurinia Pharmaceuticals business performance
Aurinia Pharmaceuticals's return on sales has increased by 36% QoQ
AUPH's ROIC is up by 26% year-on-year and by 16% since the previous quarter
The company's return on assets fell by 21% YoY but it rose by 12% QoQ
The ROE has decreased by 20% YoY but it has increased by 12% from the previous quarter

Dividends

What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AUPH.

Financial health

How did Aurinia Pharmaceuticals financials performed over time
The total liabilities has increased by 25% YoY but it has decreased by 9% from the previous quarter
Aurinia Pharmaceuticals's total assets has increased by 22% YoY but it has decreased by 7% QoQ
Aurinia Pharmaceuticals's debt is 98% lower than its equity
AUPH's equity is up by 21% year-on-year but it is down by 6% since the previous quarter
Aurinia Pharmaceuticals's debt has decreased by 3.5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.